www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over cookies op www.rijkshuisstijl.nl

Vilobelimab

Gohibic

Extended indication	Gohibic is indicated for the treatment of adult patients with SARS‑CoV2‑induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of Standard of Care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygenation (ECMO)).
Therapeutic value	No estimate possible yet
Registration phase	Positive CHMP opinion

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information

Understanding of expected market entry
of innovative medicines

Service

About this site